A medicine being approved by a NICE Technology Appraisal doesn't mean that it automatically becomes available to or used by every eligible patient. This tool intends to show the system as it really is, not how it is intended to be.
Scope. The Lite version covers medicines commissioned by ICBs following routine NICE technology appraisal. The Full version adds three further routes a medicine can take: high cost medicines, biosimilars and generics, and NHS England commissioned. Each has its own barriers and its own scope, shown at the top of that section.